Psychedelic News and Analysis Made Simple for Investors
Psychedelic Invest is a resource for those looking to invest in the burgeoning psychedelic industry.
Track the entire psychedelic market
We’ve developed the first all encompassing index to track the public psychedelic marketplace.
Explore the Index
Just Some of the Data we Cover
Latest News
Press
Apr 24
•
3 min read
VANCOUVER – MindBio Therapeutics Corp. (CSE: MBIO) (Frankfurt: WF6), (the ‘Company’ or ‘MindBio’), a clinical stage biopharma company uniquely pioneering novel treatments for psychiatric conditions using microdoses of psychedelic medicines is pleased to announce publication of its scientist’s sleep research in the prestigious Nature portfolio journal Translational Psychiatry. MindBio’s unique investment thesis in the sector, is that small,…
Press
VANCOUVER, British Columbia, April 24, 2024 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that its subsidiary Algernon NeuroScience (AGN Neuro), along with the Centre for Human Drug Research (CHDR), will present its Phase 1 stroke study data at the Interdisciplinary…
Apr 24
•
5 min read
Press
NEW YORK and BERLIN, April 24, 2024 (GLOBE NEWSWIRE) — atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the first patient has been dosed in Part 2 of Beckley Psytech’s Phase 2a study, evaluating BPL-003 (intranasal 5-MeO-DMT) in patients living with…
Apr 24
•
4 min read
Lifestyle
The ongoing legal battle between a doctor and the U.S. Drug Enforcement Administration (DEA) over the use of psychedelics, specifically psilocybin, for medical purposes is intensifying. Recently, the DEA asked the Ninth Circuit Court of Appeals to prevent a physician from using psilocybin to treat depression in terminally ill cancer patients, as reported by Law360….
Apr 23
•
3 min read
Press
TORONTO, April 23, 2024 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders, announced today that the U.S. Food & Drug Administration (“FDA”) has granted the…
Apr 23
•
3 min read
Press
SARASOTA, FL, April 23, 2024 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced positive data in the final validation report from the recent pharmacokinetic (PK) study of SPC-15, an…
Apr 23
•
3 min read
Press
Toronto, Ontario–(Newsfile Corp. – April 23, 2024) – Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) (“Red Light Holland”), a company engaged in the production, growth and sale of functional mushrooms and mushroom home grow kits in North America and Europe and a premium brand of psilocybin truffles to the legal, recreational market…
Apr 23
•
3 min read
Explore the Psychedelic Landscape
Learn more about the psychedelic companies changing the industry.